Tyk2 Kinase Inhibitors – Pipeline Insight 2022: Key Players Include Bristol-Myers Squibb, Oncostellae, Pfizer and Galapagos – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–Clinical trial “Tyk2 Kinase Inhibitors – Pipeline Insight, 2022” has been added to from ResearchAndMarkets.com offer.

This report covers pipeline drug profiles including clinical and non-clinical stage products. It also covers therapeutic evaluation by product type, stage, route of administration and molecule type. It further highlights inactive pipeline products in this space

Understanding tyk2 kinase inhibitors

Tyk2 kinase inhibitors: overview

Tyrosine kinase 2 (Tyk2) is a non-receptor tyrosine-protein kinase, an enzyme which in humans is encoded by the TYK2 gene. Tyk2, along with three other family subtypes, namely Jak1, Jak2, and Jak3, belong to the JAK family. This protein associates with the cytoplasmic domain of cytokine type I and type II receptors and promotes cytokine signals by phosphorylating the receptor subunits. It is also part of the type I and type III interferon signaling pathways. Selective inhibition of Tyk2 may provide pharmacological benefits in the treatment of many diseases such as psoriasis, systemic lupus erythematosus (SLE), inflammatory bowel disease (IBD), rheumatoid arthritis (RA), cancer and diabetes.

Report Highlights

  • Companies and academics are scrambling to assess challenges and seek out opportunities that may influence TYK2 Kinase inhibitor R&D. Therapies being developed focus on new approaches for tyk2 kinase inhibitors.

Emerging Drug Chapters on Tyk2 Kinase Inhibitors

This segment of the TYK2 Kinase Inhibitors report contains its detailed analysis of various drugs at different stages of clinical development including Phase III, II, I, Preclinical and Discovery. It also helps to understand details of clinical trials, expressive pharmacological action, agreements and collaborations, as well as the latest news and press releases.

Emerging Medicines Tyk2 Kinase Inhibitors

Deucravacitinib: Bristol-Myers Squibb

Deucravacitinib (formerly BMS 986165) is an orally available selective allosteric inhibitor of tyrosine kinase 2 (Tyk2). Deucravacitinib is being studied in multiple immune-mediated diseases, including psoriasis, psoriatic arthritis, lupus, and inflammatory bowel disease. Bristol Myers Squibb is evaluating deucravacitinib in Phase 3 clinical studies in psoriasis.

Brepocitinib: Pfizer

Brepocitinib (PF-06700841) is a selective topical inhibitor of tyrosine kinase 2 (TYK2) and janus kinase 1 (JAK1). The drug is in Phase 2 clinical studies for the potential treatment of psoriasis and atopic dermatitis in topical formulation and, in oral formulation, psoriatic arthritis, Crohn’s disease, ulcerative colitis, vitiligo , systemic lupus erythematosus, alopecia areata and hidradenitis suppurativa.

TYK2 Kinase Inhibitors: Therapeutic Review

This segment of the report provides information about the different Tyk2 Kinase Inhibitor drugs separated based on the following parameters which define the scope of the report.

Key players working on TYK2 Kinase Inhibitors

Approx. Over 15 key companies developing TYK2 Kinase Inhibitors. Among the companies whose TYK2 Kinase inhibitor drug candidates are at the most advanced stage, that is to say in phase III, we can cite Bristol-Myers Squibb.

Steps

This report covers about 15+ products under different phases of clinical development like

  • Late-stage products (Phase III and

  • Intermediate products (Phase II and

  • Early-stage products (Phase I/II and Phase I) as well as details of

  • Candidates in the preclinical and discovery phase

  • Abandoned and Inactive Candidates

  • Route of administration

The Tyk2 Kinase Inhibitors Pipeline report provides the therapeutic evaluation of the drugs in the pipeline by route of administration. Products have been categorized under various ROAs such as

  • Infusion

  • intradermal

  • Intramuscular

  • intranasal

  • intravaginal

  • Oral

  • Parenteral

  • Subcutaneous

  • Topical

  • Molecule type

The products have been categorized under different types of molecules such as

  • Vaccines

  • Monoclonal antibody

  • peptides

  • Polymer

  • small molecule

  • type of product

Drugs have been categorized into different product types like Mono, Combination and Mono/Combination.

Tyk2 Kinase Inhibitors: Pipeline Development Activities

The report provides an overview of different therapeutic candidates in phase III, II, I, preclinical and discovery. It also analyzes the main therapeutic players of tyk2 kinase inhibitor drugs involved in the development of key drugs.

Pipeline development activities

The report covers the detailed information on collaborations, acquisitions and mergers, licenses as well as an in-depth therapeutic evaluation of new TYK2 Kinase inhibitor drugs.

Tyk2 Kinase Inhibitors Report Overview

  • Tyk2 Kinase Inhibitor Pipeline Analysis

  • Therapeutic assessment

  • Unmet needs

  • Impact of drugs

Evaluation of Tyk2 Kinase Inhibitors Report

  • Pipeline Product Profiles

  • Therapeutic assessment

  • Pipeline assessment

  • Evaluation of inactive drugs

  • Unmet needs

Key questions

Current scenario and emerging therapies:

  • How many companies are developing tyk2 kinase inhibitor drugs?

  • How many tyk2 kinase inhibitor drugs are developed by each company?

  • How many pipeline drugs are in mid-stage and late-stage development for tyk2 kinase inhibitors?

  • What are the major collaborations (industry-industry, industry-academia), mergers and acquisitions, licensing activities related to tyk2 kinase inhibitor therapeutics?

  • What are the recent trends, types of drugs and new technologies developed to overcome the limitations of existing therapies?

  • What are the ongoing clinical studies for TYK2 Kinase inhibitors and their status?

  • What are the key designations that have been granted to pipeline drugs?

Key players

  • Incyte Corporation

  • Bristol Myers Squibb

  • Oncostelles

  • Pfizer

  • Galapagos

  • Haisco Pharmaceutical Group

  • Serum

  • Oncostelles

Key products

  • Baricitinib

  • Deucravacitinib

  • OST-122

  • Brepocitinib

  • GLPG-3121

  • FTP 637

  • SDC-1801

  • OST-246

For more information about this clinical trial report, visit https://www.researchandmarkets.com/r/vjqytv

Comments are closed.